Insider Selling: Phreesia, Inc. (NYSE:PHR) SVP Sells 685 Shares of Stock

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 685 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $22.86, for a total transaction of $15,659.10. Following the transaction, the senior vice president now owns 119,010 shares of the company’s stock, valued at approximately $2,720,568.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Amy Beth Vanduyn also recently made the following trade(s):

• On Monday, April 8th, Amy Beth Vanduyn sold 3,354 shares of Phreesia stock. The stock was sold at an average price of $22.62, for a total transaction of $75,867.48.

Phreesia Stock Performance

Shares of NYSE:PHR opened at $21.67 on Friday. The firm has a fifty day moving average price of $24.28 and a 200 day moving average price of $21.28. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.02. Phreesia, Inc. has a 1-year low of $12.05 and a 1-year high of $34.98.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.02. The firm had revenue of $95.00 million during the quarter, compared to analysts’ expectations of $93.52 million. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. Phreesia’s quarterly revenue was up 24.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.72) EPS. On average, equities analysts anticipate that Phreesia, Inc. will post -1.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on PHR shares. Robert W. Baird boosted their price target on shares of Phreesia from $30.00 to $31.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. JMP Securities boosted their price target on shares of Phreesia from $28.00 to $30.00 and gave the stock a “market outperform” rating in a report on Thursday, March 21st. Needham & Company LLC reiterated a “buy” rating and set a $29.00 price target on shares of Phreesia in a report on Friday, March 15th. DA Davidson reiterated a “neutral” rating and set a $32.00 price target on shares of Phreesia in a report on Friday, March 15th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $23.00 target price on shares of Phreesia in a report on Thursday, March 21st. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, Phreesia presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.62.

Institutional Trading of Phreesia

Large investors have recently bought and sold shares of the business. CI Investments Inc. boosted its stake in Phreesia by 6.6% during the 3rd quarter. CI Investments Inc. now owns 477,265 shares of the company’s stock worth $8,915,000 after purchasing an additional 29,500 shares during the period. Schroder Investment Management Group purchased a new position in Phreesia during the 3rd quarter worth $6,514,000. TimesSquare Capital Management LLC raised its position in Phreesia by 7.8% during the 3rd quarter. TimesSquare Capital Management LLC now owns 774,079 shares of the company’s stock worth $14,460,000 after buying an additional 55,793 shares during the last quarter. Trust Point Inc. purchased a new position in Phreesia during the 4th quarter worth $239,000. Finally, Lazard Asset Management LLC raised its position in Phreesia by 58.6% during the 3rd quarter. Lazard Asset Management LLC now owns 424,047 shares of the company’s stock worth $7,921,000 after buying an additional 156,711 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.